Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SCA-136 Administered Orally to Healthy Japanese Male Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00505973

Enrollment

Registered

2007-07-25

Start date

2007-07-31

Completion date

2007-10-31

Last updated

2007-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

This study is being conducted to assess the safety and tolerability of ascending multiple oral doses of SCA-136 administered to healthy Japanese male subjects.

Interventions

DRUGSCA-136

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

20 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healty Japanese men willing to use a medically acceptable form of contraception.

Exclusion criteria

* Any significant disease * Positive urine drug screen * Increased liver function tests * Use of prescription drugs.

Design outcomes

Primary

Measure	Time frame
Adverse events, safety laboratory results, vital signs, and ECGs will be used to monitor subject safety.	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026